BEAT BioTherapeutics Announces Scientific Presentations of Promising New Heart Failure Treatment at the American Heart Association Meeting

AHA Scientific Sessions 2014

SEATTLE--()--BEAT BioTherapeutics Corporation (BEATBio) announced today that there will be two scientific presentations related to its BB-R12 drug candidate for heart failure at the American Heart Association’s annual Scientific Sessions meeting in Chicago, IL. The BB-R12 gene therapy is based on the fundamental discovery that 2-Deoxy Adenosine Triphosphate (dATP) is a superior fuel for cardiac muscle contraction than is ATP. BB-R12 is being developed to treat heart failure by increasing cardiac dATP levels and cardiac muscle performance, allowing the heart to pump blood more effectively. BEATBio’s Chief Medical Officer, Dr. Sam Teichman, will present a poster, “BB-R12, A Novel Gene Therapy for Heart Failure,” during the Experimental Cardiac Regeneration and Cellular Therapy session from 3-4:30 PM on Tuesday, November 18 in the Poster Hall. Dr. Farid Moussavi-Harami, Division of Cardiology/Medicine and Department of Bioengineering at the University of Washington, will present a poster entitled 2-deoxy Adenosine Triphosphate Improves Contraction In Human End-stage Heart Failure” on Monday, November 17 from 9:30-11 AM in the Poster Hall.

“BB-R12, A Novel Gene Therapy for Heart Failure”

Dr. Teichman will present data from a recently completed proof-of-concept study in a large animal model of heart failure showing that BB-R12 therapy was safe and was associated with rapid and sustained improvements in cardiac performance. Dr. Moussavi-Harami will present data from a study of cardiac tissue samples taken from patients undergoing heart transplant that were treated with dATP that provides further support for the human therapeutic potential of BB-R12.

About BEATBio: BEATBio is a Seattle, WA-based biotechnology company focused on the development of BB-R12, a novel biological treatment for heart failure. BEATBio’s founders, from the University of Washington, are recognized experts in cardiovascular biology, muscle physiology and bioengineering and have received nearly $50MM of NIH funding. BEATBio holds exclusive, worldwide rights to the BB-R12 technology they developed and has used a recently raised $4 million seed financing to successfully complete the initial stages of pre-clinical development and manufacturing scale-up. BEATBio has assembled a strong team of experts that has allowed rapid achievement of significant development milestones in 2013-2014. The company is now raising a Series A financing to complete IND-enabling studies and complete Phase I human trials.


Michael Kranda, CEO, 425-647-4236 (mobile)
Sam L. Teichman, CMO, 925-437-2067 (mobile)


Release Summary

BEAT BioTherapeutics (BEATBio) Announces Two Scientific Presentations of Promising New Heart Failure Treatment Taking Place at American Heart Association's Scientific Session on November 17th and 18th

BEAT BioTherapeutics Corporation